Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- DRUG: Retatrutide
- DRUG: Placebo
Sponsor
Eli Lilly and Company